Promising lymphoma combo trial halted after just 8 patients

NCT ID NCT04541017

Terminated Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested two lab-made antibodies, magrolimab and mogamulizumab, together in people with a type of T-cell lymphoma (mycosis fungoides or Sezary syndrome) that had returned or stopped responding to prior treatments. The goal was to find the best dose and see if the combination could shrink tumors or slow the disease. However, the study was terminated early after enrolling only 8 participants, so we have very little information about how well it worked or what side effects occurred.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Magrolimab and mogamulizumab (monoclonal antibodies)
What this could lead to: If it had succeeded, this combination might have offered a new option for patients with T-cell lymphoma that stopped responding to other treatments.
What could go wrong: The trial was terminated early with only 8 participants, so results are very limited. It is unclear if the combination is safe or effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mycosis fungoides Sezary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYCOSIS FUNGOIDES RECURRENT MYCOSIS FUNGOIDES RECURRENT MYCOSIS FUNGOIDES AND SEZARY SYNDROME RECURRENT SEZARY SYNDROME REFRACTORY MYCOSIS FUNGOIDES REFRACTORY MYCOSIS FUNGOIDES AND SEZARY SYNDROME REFRACTORY SEZARY SYNDROME SEZARY SYNDROME STAGE IB MYCOSIS FUNGOIDES AND SEZARY SYNDROME AJCC V8 STAGE II MYCOSIS FUNGOIDES AND SEZARY SYNDROME AJCC V8 STAGE III MYCOSIS FUNGOIDES AND SEZARY SYNDROME AJCC V8 STAGE IV MYCOSIS FUNGOIDES AND SEZARY SYNDROME AJCC V8

Contacts and locations

Locations

City of Hope Comprehensive Cancer Center

Duarte, California, 91010, United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone

New York, New York, 10016, United States
Los Angeles General Medical Center

Los Angeles, California, 90033, United States
Memorial Sloan Kettering Basking Ridge

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Memorial Sloan Kettering Commack

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Westchester

Harrison, New York, 10604, United States
NYP/Weill Cornell Medical Center

New York, New York, 10065, United States
Northwestern University

Chicago, Illinois, 60611, United States
Stanford Cancer Institute Palo Alto

Palo Alto, California, 94304, United States
USC / Norris Comprehensive Cancer Center

Los Angeles, California, 90033, United States
University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104, United States
University of Wisconsin Carbone Cancer Center - University Hospital

Madison, Wisconsin, 53792, United States
Wake Forest University Health Sciences

Winston-Salem, North Carolina, 27157, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.